Israeli analysis suggests South African COVID-19 strain can ‘break through’ the Pfizer vaccine.

Spread the love

A real-world data analysis in Israel discovered that the coronavirus strain discovered in South Africa can “break through” Pfizer/COVID-19 BioNTech’s vaccine to some degree, despite the fact that its prevalence in the country is poor and the testing has not been peer reviewed.

The study, which was published on Saturday, compared about 400 individuals who tested positive for COVID-19 14 days or more after receiving one or two doses of the vaccine to the same number of unvaccinated patients with the disease. It balanced age and gender, among other things.

According to a survey conducted by Tel Aviv University and Israel’s largest healthcare provider, Clalit, the South African version, B.1.351, accounted for around 1% of all COVID-19 cases surveyed.

However, the prevalence of the variant was eight times higher in patients who had administered two doses of the vaccine than in those who had not – 5.4 percent versus 0.7 percent.

According to the experts, this means that the vaccine is less successful against the South African strain as compared to the original coronavirus and a variant first reported in Britain that has come to account for almost all COVID-19 cases in Israel.

READ ALSO:  UK COVID-19 infections rise as ministers fret over second wave in Europe

“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.

The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.

They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.

Pfizer and BioNTech could not be immediately reached for comment outside business hours.

The companies said on April 1 that their vaccine was around 91% effective at preventing COVID-19, citing updated trial data that included participants inoculated for up to six months.

In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of COVID-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.

READ ALSO:  Nigeria announces 561 fresh cases of COVID-19, 17 deaths within the last 24 hours

Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a robust defence.

While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Stern.

“Even if the South African variant does break through the vaccine’s protection, it has not spread widely through the population,” said Stern, adding that the British variant may be “blocking” the spread of the South African strain.

Almost 53% of Israel’s 9.3 million population has received both Pfizer doses. Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding, with infection rates, severe illness and hospitalizations dropping sharply. About a third of Israelis are below the age of 16, which means they are still not eligible for the shot.


Leave a Reply